Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
211914-51-1
Molecular formula
C25H25N7O3
Molecular weight
471.5 g/mol
Drug class
Direct thrombin inhibitoractive moiety released from dabigatran etexilate prodrug
Mechanism of action
Directly and competitively inhibits free and clot-bound thrombin (factor IIa), preventing fibrin formation and thrombin-mediated platelet activation. In clinical products, dabigatran is delivered as the active metabolite after hydrolysis of dabigatran etexilate.
Indications / reported uses
Prevention of stroke and systemic embolism in eligible adults with non-valvular atrial fibrillation
Treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) after initial parenteral anticoagulation and reduction of recurrence risk
Prevention of venous thromboembolism following hip replacement surgery in adults; specific indications, age criteria and renal-dose restrictions are label-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dabigatran Environmental Risk Assessment (ERA) (the Dabigatran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.